Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

作者：Ruben A. Mesa, Harinder Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken‐Hong Lim, Sung‐Eun Lee, Sung Hwa Bae, Winnie Z.Y. Teo, Dawn Maze, Stephen T. Oh, Prithviraj Bose, Toshiaki Sato, Oleh Zagrijtschuk, Sheena Lin, Weichung Joe Shih, John Mascarenhas, Lucia Masárová · 发表于：The Lancet Haematology · 年份：2025 · DOI：10.1016/s2352-3026(25)00264-9 · 被引用次数：8 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Platelet Disorders and Treatments、Hemophilia Treatment and Research